Liposomal doxorubicin in breast cancer

Author： Shehata M   Mukherjee A   Sharma R   Chan S  

Publisher： Future Medicine

ISSN： 1745-5057

Source： Women's Health, Vol.3, Iss.5, 2007-09, pp. : 557-569

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Trastuzumab Combined with Pegylated Liposomal Doxorubicin in Patients with Metastatic Breast Cancer

By  

Oncology, Vol. 76, Iss. 4, 2009-03 ,pp. : 275-285

Karger

Access to resources Recommend Favorite

Pegylated Liposomal Doxorubicin (Caelyx®) in Metastatic Breast Cancer: A Community-Based Observation Study

By  

Oncology, Vol. 72, Iss. 3-4, 2007-12 ,pp. : 147-151

Karger

Access to resources Recommend Favorite

Phase II Trial of Pegylated Liposomal Doxorubicin-Cyclophosphamide Combination as First-Line Chemotherapy in Older Metastatic Breast Cancer Patients

By  

Oncology, Vol. 73, Iss. 3-4, 2008-04 ,pp. : 210-214

Karger

Access to resources Recommend Favorite

Pegylated Liposomal Doxorubicin-Induced Acute Transient Encephalopathy in a Patient with Breast Cancer: A Case Report

By  

Case Reports in Oncology, Vol. 7, Iss. 1, 2014-03 ,pp. : 228-232

Karger

Access to resources Recommend Favorite

Pegylated Liposomal Doxorubicin with Vinorelbine in Metastatic Breast Carcinoma

By  

Oncology, Vol. 63, Iss. 1, 2002-08 ,pp. : 23-30

Karger

Access to resources Recommend Favorite